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5Abstract
Objectives: Characterization of HIV-1 from slow progressors (SP) is important to facilitate
vaccine and antiviral drug development. In order to identify virus attenuations that may
contribute to slower rates of disease progression, the full viral genomes from primary
isolates of six slow progressing HIV-positive children were sequenced.
Methods: Primary virus biological phenotypes were determined by growth in CCR5- and
CXCR4-expressing U87.CD4 cell lines. Proviral DNA was isolated from co-cultured PBMCs,
and the near full-length genomes and LTR regions were PCR amplified, sequenced and
analysed. Predicted amino acid (aa) sequences for all the HIV-1 proteins were extensively
analyzed.
Results: All primary HIV-1 isolates utilized CCR5, and were determined to be HIV-1 subtype
C by phylogenetic analysis. Predicted aa sequence analysis revealed open reading frames for
all HIV-1 genes which encoded for proteins of the expected length, with several exceptions.
For example, isolate LT5 had a 2 aa insertion in the Vpr mitochondriotoxic domain. Isolate
LT21 contained an additional 5aa in the C-terminus of tat exon 2, while the integrase
enzyme in isolate LT39 had an additional 3aa at the C-terminus. Rev from isolates LT45 and
LT46 did not have the characteristic subtype C 16aa truncation, and in addition, had a
further 3aa. In addition, altered functional domains was noted in several isolates, such as
the cAMP-dependent kinase PKA phosphorylation site in Nef (LT5), a Vpr mutation involved
in decreasing pro-apoptotic activity (LT42), and the Nef ExxxLL motif involved in the
interaction with AP-1 and AP-2 (LT46).
Conclusions: The slower HIV disease progression in these six children may be attributed to
altered protein functions. For example, LT46 Nef is unable to bind AP-1 and AP-2 and
therefore inactive on CD4 endocytosis. The biological relevance of these findings requires
further investigation.
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Figure 1.1: Typical course of the natural history of viral loads (HIV RNA levels)
and CD4 counts at three rates of disease progression to AIDS (copied from
Langford SE et al, 2007).
Figure 1.2: Schematic representation of the HIV-1 viral life cycle. Infection is
initiated when free virions (top left) attach to CD4 + T lymphocytes via their CD4
receptor. (Copied from Peterlin and Trono, 2003).
Figure 3.1: Representative agarose gel electrophoresis (1%) of the near full-
length PCR (~9.4kb, Lanes 1 to 5) and LTR PCR amplicons (~0.45-1.2 kb, Lanes 6
to 10) from the newly characterized HIV-1 subtype C isolates. The sizes of the
molecular weight marker (M; Roche) are indicated on the right.
Figure 3.2: Phylogenetic relationships of the near full-length genomes of the six
newly characterized subtype C viruses, with HIV-1 group M subtype reference
sequences from the Los Alamos database. The newly sequenced genes are
shown in blue italics. Phylogenetic trees were constructed from nucleotide
alignments, using neighbour joining and the Kimura two-parameter distance
matrix. The reliability of the branching order was estimated from 100 bootstrap
replicates, and only bootstrap values of 70% or higher are shown.
Figure 3.3: Phylogenetic relationships of the LTR regions of the six newly
characterized subtype C viruses with HIV-1 subtype reference sequences from
the Los Alamos database. The new sequences are shown in blue italics. Only
bootstrap values of 70% or higher are shown. Phylogenetic trees were
constructed from nucleotide alignments, using neighbour joining and the
Kimura two-parameter distance matrix. The reliability of the branching order
was estimated from 100 bootstrap replicates, and only bootstrap values of 70%
or higher are shown.
Figure 3.4: Alignment of the predicted amino acid sequences for the Integrase
enzymes from the six newly characterized subtype C viruses and comparison to
the consensus C and ancestral C sequences obtained from Los Alamos
(www.hiv.lanl.gov). The unusual motif at the C-terminus of the LT39 integrase
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Figure 3.5: Alignment of the predicted amino acid sequences for the viral
protein R (Vpr) from the six newly characterized subtype C viruses and
comparison to the consensus C and ancestral C sequences obtained from Los
Alamos (www.hiv.lanl.gov). The unusual 2 amino acid insertion at the C-
terminus of LT5 Vpr is shown in red. Position 77 is highlighted in blue. The dots
represent identical amino acids, and dashes indicate insertions/deletions.
Figure 3.6: Alignment of the predicted amino acid sequences for Tat from the
six newly characterized subtype C viruses and comparison to the consensus C
and ancestral C sequences obtained from Los Alamos (www.hiv.lanl.gov). The
unusual motif at the C-terminus of LT21 is shown in blue. The cysteine rich
motif is highlighted in red. The dots represent identical amino acids, and dashes
indicate insertions/deletions.
Figure 3.7: Alignment of the predicted amino acid sequences for Rev from the
six newly characterized subtype C viruses and comparison to the consensus C
and ancestral C sequences obtained from Los Alamos (www.hiv.lanl.gov). The
unusual three amino acid insertion at the C-terminus of LT45 and LT46 is shown
in blue. The dots represent identical amino acids, and dashes indicate
insertions/deletions.
Figure 3.8: Alignment of the predicted amino acid sequences for Nef from the
six newly characterized subtype C viruses and comparison to the consensus C
and ancestral C sequences obtained from Los Alamos (www.hiv.lanl.gov).
Position 9 is highlighted in pink, and the ExxCLL motif is shown in blue. The dots
represent identical amino acids, and dashes indicate insertions/deletions.
Figure 3.9: Alignment of the predicted V3 amino acid sequences of the 6 newly
characterized HIV-1 subtype C isolates. The sequences are compared to the HIV-
1 subtype C consensus and ancestral sequence (www.hiv.lanl.gov). The overall
positive charge, number of amino acids, phenotype and biotype of each isolate
is shown on the right. Dashes (-) indicate deletions/insertions, and positions 11
(green) and 25 (pink) and the V3 crown/tip (yellow) are highlighted.
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1. INTRODUCTION
Globally there are currently over 34 million people infected with human immunodeficiency
virus (HIV), the causative agents of acquired immune deficiency disease (AIDS)
(http://www.unaids.org), and over 25 million people have died of AIDS since the start of the
pandemic in the early 1980s. HIV type 1 (HIV-1) and HIV type 2 (HIV-2) are retroviruses
which, upon infection causes the progressive depletion of CD4+ T cells which are central in
establishing and enhancing adaptive (cell-mediated and humoral) immune responses. This
ultimately leads to vulnerability to common opportunistic infections, malignancies and
death in the absence of antiretroviral therapy.
Rates of disease progression to AIDS amongst HIV-1 infected patients are highly variable and
depend on a complex interplay between the host’s genetic factors, immunological
responses (reviewed by (Lama and Planelles, 2007) and the pathogenic potential of the virus
(Pantaleo, Graziosi, and Fauci, 1993). These factors are interrelated and inextricably
interdependent: the antigenicity and pathogenicity of the virus dependents on its own
genetic complement, which in turn is altered by the host’s specific immune responses which
depend on the host’s genetic constitution (especially human leukocyte antigen (HLA) loci).
1.1. Natural history of HIV infection
The natural history of HIV infection and disease progression has been well established in
adults, particularly in those infected with HIV-1 subtype B. The median time from infection to
development of AIDS is approximately 10 years for intermediate progressors (Langford,
Ananworanich, and Cooper, 2007); Figure 1.1). The clinical course of disease progression can
be divided into three phases; the acute phase or primary infection, the asymptomatic phase,
and AIDS (Figure 1.1). Upon infection, HIV-1 replicates uncontrollably and HIV viral loads
(RNA copies/ml) are extremely high (acute phase). This leads to a depletion of CD4+ T cells
(cells/mm3 or µl). Cellular immune responses (CD8+ cytotoxic T-lymphocyte (CTLs)) are
mounted against HIV-1 to control the viral load at a set point, and the CD4+ cell counts
recover (asymptomatic phase). The viral set point varies amongst patients, and it is well
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established that the lower the set point, the slower the disease progression to AIDS. There is
ongoing viral replication throughout the course of disease, and gradual loss of immune
function. Once the CD4 counts drop to below 200 CD4 cells/µl, the individual is diagnosed
with AIDS.
A small proportion of adult patients develop AIDS as early as 3 to 6 months post infection
(rapid progressors)(Pantaleo and Fauci, 1996), or remain clinically asymptomatic (5% of
infected patients) after 7-10 years in the absence of antiretroviral therapy (slow progressors
(SP) or long term non-progressors, LTNP, (Learmont et al., 1992) (Figure 1.1). More recently,
a subset of infected individuals (elite controllers) with spontaneous and sustained control of
HIV infection, with viral loads <50 RNA copies/ml in the absence of therapy have been
described (Pereyra et al., 2008; Walker, 2007). This spontaneous control occurs in
approximately 1 in 300 HIV-infected persons, and the HIV Controller Consortium was
recently established to study host genetics together with functional immunology studies in
elite controllers (www.elitecontrollers.org).
By contrast, children with vertically acquired HIV-1 infection tend to have shorter clinical
latent periods and survival times than HIV-1 infected adults (Saloojee and Violari, 2001). In
the developed world approximately 20% of children progress rapidly to AIDS within the first
2 years after birth (reviewed in (Saloojee and Violari, 2001)) whereas in sub-Saharan Africa
up to 50% of children are RP (rapid progressors) (Little et al., 2007)). Asymptomatic
vertically infected children older than 7 years of age are unusual (Paul, 1997), and in a
recent prospective study of the ANRS French Pediatric Cohort, only 2% of children infected
showed no clinical progression at 10 years (Warszawski et al., 2007).
Interest in non-progressive HIV-1 infection has increased over time in the hope of
understanding HIV pathogenesis and the mechanisms of protection involved, and providing
insights relevant to viral attenuation, novel therapies and vaccine design (Walker, 2007). SP
or LTNP cohorts provide a unique opportunity to study the complexity of the virus-host
interaction with the aim of understanding the biological and molecular correlates of
protection against HIV-1 infection and disease progression.
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The duration of clinical latency following HIV-1 infection is regulated by the interplay of at
least three virus-host factors: (i) genetic susceptibility of the host, (ii) the hosts ability to
mount an effective immune response, and (iii) the genotypic properties of the infecting viral
quasispecies (Alexander et al., 2000; Sheppard et al., 1993).
Figure 1.4: Typical course of the natural history of viral loads (HIV RNA levels) and CD4
counts at three rates of disease progression to AIDS (copied from (Langford, Ananworanich,
and Cooper, 2007).
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1.2. Host Factors impacting on HIV-1 disease progression
1.2.1. Immune factors.
Most research on LTNP patients has focused on the characterization of the specific antiviral
host immune responses thought to be responsible for modulating disease progression.
There are vigorous HIV-specific CD4+ T helper (Th1) cell responses in non-progressors,
whereas these responses are absent or low in typical progressors (Rosenberg et al., 1997).
LTNPs are more likely to develop strong neutralizing antibodies against HIV (Cecilia et al.,
1999). Humoral immunity has, however, been shown to vary amongst HIV-1 subtype C
vertically infected children but is not predictive of disease progression (Zhang et al., 2006).
Antibodies against the CCR5 coreceptors have also been identified in a subset of adult
LTNP’s (Pastori et al., 2006) and have also been shown to block infection of macrophages
and dendritic cells with R5 viruses (Bouhlal et al., 2005). In addition, LTNPS are more likely
to develop strong and persistent cytotoxic T-lymphocyte (CTL) responses against several
HIV-1 epitopes (Greenough et al., 1997; Harrer et al., 1996), albeit with viral attenuation
(Cao et al., 1995).
1.2.2. Host genetics.
Susceptibility to HIV infection and disease progression can also be influenced by diverse
host genetic factors such as the extent of heterozygosity at major histocompatibility
complex class I (MHC-I) loci (Altfeld et al., 2006; Carrington et al., 1999; Carrington and
O'Brien, 2003) and polymorphisms in the HIV-1 coreceptors CCR5 (Liu et al., 1996) and
CXCR4 (Winkler et al., 1998).
1.2.2.1. Human Leukocyte Antigen
The role of HLA is to clearly define the repertoire of the CD8+ epitope-restricted responses
in HIV infection (Altfeld et al., 2006). The influence of HLA genotype on HIV response and
disease progression has been reviewed by (Carrington and O'Brien, 2003). It has been
demonstrated that the HLA background contributes to disease modification, where the
presence of HLA-B27 (Goulder et al., 1997) and HLA-B57 (Migueles et al., 2000) appears to
be linked to slower disease whereas with HLA-B35, the disease outcome is worse.
Interestingly, Fellay et al. (2007) used a whole genome association strategy and identified a
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polymorphism within an endogenous retroviral element which is associated with HLA-
B*5701, and another near the HLA-C gene which impact on lowering viral load during the
asymptomatic set-point period preceding disease progression to AIDS.
1.2.2.2. Gene polymorphisms
Approximately 25-30% of LTNP have polymorphisms in their HIV-1 coreceptors CCR5 and
CCR2, and express mutant forms of these proteins. People that are homozygous for a 32-bp
deletion in CCR5 are resistant to infection by CCR5-utilizing HIV-1 strains (Agrawal et al.,
2004; Liu et al., 1996). This loss of function mutation prevents expression of the essential co-
receptor (CCR5) for HIV attachment (Dean et al., 1996). Interestingly, heterozygosity for the
32-bp deletion in the CCR5 gene is associated with longer AIDS-free survival. Whether this is
true for vertically infected children is debatable (de Angelis et al., 2007).
Chemokines have been shown to play a major role in HIV pathogenesis. Stromal Derived
Factor -1 (SDF-1 or CXCL 12) the only known natural ligand for CXCR4, one of the two major
coreceptors for cell viral entry for HIV-1 (reviewed by (Littman, 1998) is capable of blocking
viral entry (Bleul et al., 1996). Patients who express the SDF 1-3’A variant are also associated
with delayed disease progression (Fauci, 1996; Winkler et al., 1998). This polymorphism has
however been shown not to be associated with LTNP disease of longer than 16 years in HIV-
1 infected patients (Vidal et al., 2005).
The presence of polymorphisms such as H186R in the antiviral APOBEC3G (Apolipoprotein B
mRNA editing enzyme, catalytic polypeptide-like 3G) have been linked to accelerated
progression to AIDS in African American populations (An et al., 2004). APOBEC3G is a
cytidine deaminase which is responsible for hypermutation of the HIV-1 genome (G-to-A)
and is inactivated by the viral encoded vif protein (Sheehy et al., 2002).Binding of Vif to
APOBEC3G results in ubiquitination and subsequent proteosomal degradation of APOBEC3G
.
The whole genome association study by Fellay et al (2007) also implicated polymorphisms in
and near the ring finger protein 39 (RNF39) and zinc ribbon domain-containing 1 (ZNRD1)
genes that were associated with time of disease progression to AIDS.
18
1.2.3. Co-infections.
Human co-infection of HIV-1 with other viruses such as Human T-cell lymphotropic Virus
(Casoli, Pilotti, and Bertazzoni, 2007), Herpes simplex virus type 2 (Casoli, Pilotti, and
Bertazzoni, 2007), Varicella zoster virus (Hung et al., 2005) and cytomegalovirus (Saillour et
al., 1998) are associated with an increased rate of disease progression to AIDS. Interestingly,
infections with helminths shift the immune response from Th1 response to a less protective
Th0/2 type response (reviewed in (Bentwich et al., 2000). It appears that the
aforementioned infections result in a more rapid progression to AIDS. Similarly, malaria has
been associated with increases in HIV-1 viral load that may impact HIV progression in co-
infected individuals (reviewed in (Slutsker and Marston, 2007).
By contrast, coinfection with GBV-C (hepatitis G virus) has been shown to result in a lower
mean viral load and a higher mean CD4 cell count and subsequent retardation of disease
progression (Tillmann et al., 2001). The latter findings have however, been disputed
(Bjorkman et al., 2004) although these effects may be only noted in advanced HIV infection.
1.3. Viral Factors impacting on HIV-1 disease progression
Several viral factors that may impact on disease progression have been described.
Controversy abounds in the literature with respect to their relevance. Infection with
attenuated HIV viruses and/or mutations in functional sites of viral genes and proteins may
impact on disease progression.
1.3.1. HIV-1 genome and gene functions
The HIV-1 full-length genome (~9.7kb) encodes 9 genes and is flanked by two identical Long
Terminal Repeats (LTRs) (http://www.hiv.lanl.gov). The viral genes have been classified into
3 structural genes which include gag, pol and env, the 2 regulatory genes tat and rev, and
four accessory genes which comprise of vif, vpr, vpu and nef genes which code for at least
16 distinct viral proteins. The gene sequences and the function of their products have been
extensively studied (Table 1.1).
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Table 1.1: Schematic representation of the HIV-1 genome organisation and HIV-1 derived
proteins (top row), and description of the function and localization of each HIV-1 protein
(adapted from http://www.hiv.lanl.gov and (Levy, 2007).
Name Size Function Localization
Gag MA
CA
NC
p17
p24
p7
p6
Matrix, Membrane anchor, env interaction, myristolated
Core capsid
Nucleocapsid, helps in reverse transcription
Binds Vpr, role in viral budding (L domain)
Virion
Pol PR
RT
RNase H
IN
p15
p51
p66
p31
Gag/pol cleavage and maturation
Reverse transcription
RNAse H activity
cDNA provirus integration
Virion
Env gp120
gp41
External viral glycoproteins, bind to CD4 and
coreceptor
Transmembrane subunit
Plasma membrane,
Virion envelope
Tat p16/p14 Viral transcriptional activator Nucleolus/nucleus
Rev p19 Regulation of viral mRNA expression, RNA transport,
stability and utilization factor
Nucleolus/nucleus
Vif p23 Promotes viral maturation and infectivity; inhibits
APOBEC3G
Cytoplasm, virion
Vpr* p10-15 Transactivation, promotes nuclear localization of
preintegration complex, inhibits cell division, arrest
cells in G2/M
Virion, nucleus
(nuclear membrane?)
Vpu p16 Promotes extracellular release of virion, degrades CD4
in the ER
Integral membrane
protein
Nef p27-p25 Pleiotropic, CD4 and MHC class I downregulation, can
increase or decrease viral replication
Plasma membrane,
cytoplasm
*Vpx in HIV-2 and SIV
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1.3.2. HIV-1 life cycle
An overview of the viral life cycle is shown in Figure 1.2. HIV infection of a CD4+ T
lymphocyte is initiated when the viral gp120 binds to CD4 (Dalgleish et al., 1984; Klatzmann
et al., 1984). This leads to conformational changes on the gp120 allowing co-receptor
binding (CCR5 or CXCR4)(Deng et al., 1996; Dragic et al., 1996; Wyatt and Sodroski, 1998).
The gp120 is shed, and the gp41 fusion peptide is formed which leads to fusion of viral and
host membranes (Gallo et al., 2003; Weissenhorn et al., 1997). Once inside the cytoplasm,
the viral p24 core is uncoated and releases the 2 copies of plus strand viral RNA and other
viral proteins. The reverse transcriptase (RT) enzyme initiates reverse transcription of the
viral RNA to cDNA (Fassati and Goff, 2001). The viral cDNA aggregates with the integrase
enzyme, Vpr and other viral and host proteins to form the preintegration compex
(PIC)(Marchand et al., 2006; Van Maele et al., 2006). The PIC localizes to the nucleus where
the integrase enzyme initiates strand transfer leading to the irreversible integration of viral
cDNA into the host chromosome (Mitchell et al., 2004). Following transcription and
translation of the viral proteins, the viral protease enzyme cleaves specific viral
polyproteins, and viral RNA and proteins assemble at the host membrane, leading to
budding of an immature virion. Further maturation results in fully infectious viruses capable
of initiating a new cycle of infection.
HIV is extremely efficient at reproduction, producing over ten billion particles daily in an
average HIV-positive patient (one replication cycle takes about 2.5 days) (Ho et al., 1995;
Wei et al., 1995). Because RT is error prone it introduces mistakes during each replication
cycle, resulting in different viral quasispecies within the host (Roberts et al., 1988).
Consequently HIV evolves rapidly, and can escape host immune surveillance, and rapidly
establish drug resistant variants. Viral diversity presents the greatest challenge towards the
development of effective antiretroviral drugs and HIV-1 vaccines (Papathanasopoulos et al.,
2003).
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Figure 1.2: Schematic representation of the HIV-1 viral life cycle. Infection is initiated when
free virions (top left) attach to CD4 + T lymphocytes via their CD4 receptor. (Copied from
(Peterlin and Trono, 2003).
1.3.2.1. Viral subtype
The rapid ongoing evolution of HIV-1 results in extensive genetic diversity within a patient as
well as between different isolates. There are three different groups of HIV-1 globally (M, N
and O). HIV-1 group M is responsible for the pandemic worldwide, and is further subdivided
into 9 distinct subtypes (A to K) and at least 43 circulating recombinant forms
(http://www.hiv.lanl.gov). The subtype of the infecting virus may influence the rate of HIV
disease progression to AIDS: in Senegal, patients infected with non A subtypes, such as C, D
and G were shown to be 8 times more likely to progress to AIDS than those infected with
subtype A (Kanki et al., 1999). Similarly, in Uganda subtype D was associated with faster
disease progression compared to subtype A (Kaleebu et al., 2002). These findings were again
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confirmed in a recent study in Rakai, Uganda, where the risk of progression to death was
shown to be significantly higher for subtype D, recombinant subtypes, and multiple
subtypes, as compared with subtype A (Kiwanuka et al., 2008).
1.3.2.2. Viral Biotype/Phenotype
Viral characteristics such as cell tropism, cytopathicity and replicative capacity have been
associated with different stages of infection, suggesting an important role for HIV-1
phenotype in the clinical course of HIV infection. On sexual, vertical and parenteral
transmission, infection seems to be initiated by CCR5-utilizing macrophage tropic (M-tropic)
variants, while a shift to preferentially CXCR4-utilizing (T-tropic) HIV-1 populations is
correlated with progression to disease (Connor et al., 1997; Koot et al., 1993; Koot et al.,
1999; Koot et al., 1992). Patients infected with HIV-1 that exhibits the biological phenotype
CCR5 (non-syncytium inducing (NSI) viral phenotype) appear to progress slower than the
CXCR4 syncytium inducing (SI) phenotype. HIV-1 predominantly utilizes the CCR5 coreceptor
for cell entry in early infection and during the asymptomatic phase of the disease. However,
as the patient progresses to AIDS, a “switch”/emergence to CXCR4-utilizing viruses occur in
approximately 50-90% of subtype B infected patients (Koot et al., 1993). It is arguable
whether the emergence of the X4 viruses is a consequence or the cause for the rapid
progression (reviewed in (Lusso, 2006)).
1.3.3. Viral attenuation
Limited information is available on the genotypic properties of infecting viral quasispecies
that could contribute to the delay in, or absence of disease progression. However,
persistence of defective and/or attenuated HIV genomes has been correlated with low
replicative capacity and the lack of disease progression in at least some individuals.
1.3.3.1. Gene polymorphisms associated with attenuated viruses and delayed disease
progression
The most studied defects associated with the absence of disease progression have been
found in the nef/LTR region as documented in an asymptomatic patient from central
Massachusetts (Kirchhoff et al., 1995) and eight patients in the Sydney Blood Bank Cohort
(SBBC) (Deacon et al., 1995; Learmont et al., 1992). Full-length sequence analysis of the HIV-
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1 genome from four Sydney cohort members confirmed that the deletions and
rearrangements of the nef/LTR region were the most unusual features of these viruses
(Oelrichs et al., 1998). Similar deletions have been found in a slow progressing Italian
individual who acquired HIV-1 via sexual transmission (Salvi et al., 1998). Thus, infection
with attenuated HIV-1 is responsible for slow or no progression in these patients.
Interestingly, Geffin et al. (2000) found that one of five slow progressing HIV-1 vertically
infected children harboured a virus with large deletions in nef and the remaining four
contained discrete changes at a higher frequency compared to rapid progressors.
Subsequently, numerous researchers have described “defective” nef alleles which impact on
disease progression in various paediatric and adult cohorts (Brambilla et al., 1999; Catucci et
al., 2000; Crotti et al., 2006; Kondo et al., 2005; Salvi et al., 1998; Tobiume et al., 2002;
Verity et al., 2007; Walker et al., 2007).
The number of LTNP individuals exceeds by far the number of individuals infected with nef-
deleted HIV strains, suggesting that host factors or defects in other viral genes may
contribute significantly to their long-term survival. Several researchers have found LTNP
with unusual or defective genes other than nef/LTR, including gag, env, vpu, vpr, vif, rev and
tat genes (Alexander et al., 2002; Cho and Jung, 2008; Churchill et al., 2007; Huang, Zhang,
and Ho, 1998; Iversen et al., 1995; Papathanasopoulos et al., 2003; Wang et al., 1996;
Yamada and Iwamoto, 2000).
An LTNP with deficient activity in the viral rev gene has been described (Iversen et al., 1995).
The authors demonstrated that a leucine-to-isoleucine substitution in the Rev activation
domain contributed to virus attenuation in vitro. Slower disease progression in perinatally
infected siblings may be partly attributed to an unusual 3 amino acid sequence extension
(GCC) at the 3’end of Rev (Papathanasopoulos et al., 2003). Attenuated rev alleles in viruses
from two of 4 studied SBBC members (in addition to nef/LTR) may contribute to viral
attenuation and long-term survival of HIV-1 infection (Churchill et al., 2007).
Another LTNP with a consistently defective viral p17 sequence (Huang, Zhang, and Ho, 1998)
and a non-progressing infant-mother pair infected with Vpr defective virus (Wang et al.,
1996) have been identified. The R77Q mutation in Vpr has been associated with long term
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control of HIV-1 infection in several studies (Mologni et al., 2006; Rajan et al., 2006; Rodes
et al., 2004)). Yamada and Iwamoto (Yamada and Iwamoto, 2000) compared the proviral
accessory genes of LTNP and progressors, and found that LTNP frequently harboured
proviruses with mutated nef, vpu, vpr, vif, rev and tat genes, while almost all accessory
genes in typical progressors were intact. Wang et al. (2000) found a V2 region extension of
the gp160 unique to SP or LTNP.
Most of the abovementioned studies however, only looked at specific HIV-1 genes and their
function and not the entire genome. Therefore, unlike the nef mutants described in the
SBBC one cannot exclude the possibility that other defective genes may contribute or be
responsible for viral attenuation. Alexander et al. (Alexander et al., 2000) however,
examined the full genome sequences of eight individuals with slow or non-progressing
disease. Seven of the eight patients were infected with virus containing one or more
unusual polymorphisms, such as a one amino acid deletion in gp41, 4 amino acid insertions
in Vpu, a 1-2 amino acid deletion in Gag, and deletions in Nef. Analysis of stored PBMC
samples (ranging from 11 years prior sequencing to 4 years post sequencing for different
samples) confirmed the viruses contained genes with unusual, difficult-to-revert
polymorphisms, and these could be associated with slow or non-progression in these
patients. The same group (Alexander et al., 2002) also described defective HIV-1 from a
clinical nonprogressing mother and child pair with a two amino acid insertion in Vif
responsible for their nonprogressor status. Functional studies with PBMC infections of
recombinant HIV-1 containing the mutant or wild type Vif showed that the mutant’s
replication rate was approximately 20-fold lower than that of the wild type. Full genome
sequencing and functional analysis of defective genes is thus an important way to establish
an association between structural or functional alterations in various HIV-1 genes and the
degree of disease.
1.4. Reasons for studying SP or LTNPs, and aims of study
Strong suppression of HIV-1 replication by highly active antiretroviral therapy (HAART)
results in reconstitution of the immune system damaged by HIV-1 infection. As a
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consequence, opportunistic infections and AIDS-related deaths have dramatically decreased
since the introduction of HAART. However, immune reconstitution by highly active
antiretroviral therapy (HAART) is only partial, and the immune responses against HIV-1
appear to be lost during the course of HAART (Rinaldo et al., 1999). On the other hand, LTNP
have low viral loads and stable CD4 T cell counts, while maintaining strong anti-HIV humoral
and cellular immunity (Cao et al., 1995). The presence of viral defects in LTNP tends to be
associated with extremely low viral loads, and in several instances it has not been possible
to recover HIV-1 isolates from plasma or other tissues (Cao et al., 1995). Despite this,
immune responses to HIV-1 antigens are strong in LTNP, usually more so than in individuals
with progressive infection (Cao et al., 1995; Montefiori et al., 1996). This raises the question
of what drives the antigen-specific immune responses during such low levels of virus
replication. The presence of quasispecies in viruses with mutated genes implies their
replication, which suggests that they act as continuous immune stimulators for the patients.
Although the mechanisms for long-term non-progression have not been elucidated, LTNP
may harbour HIV-1 genomes that behave as live attenuated vaccines. The characterization
of proviral genomes from LTNP can potentially help to gain insight into the design of potent
therapeutic vaccines (Deeks and Walker, 2007).
Available evidence suggests that disease progression is a complex process, and justifies the
need for studying different cohorts of patients infected with different HIV subtypes. South
Africa has one of the fastest growing HIV-1 epidemics, with an estimated 6.2 million infected
people (http://www.unaids.org). HIV-1 subtype C currently accounts for over 50% of all new
infections by HIV-1 group M viruses worldwide, and is the major subtype responsible for the
epidemic among South African heterosexuals (Van Harmelen et al., 1999). To date, the only
report on the relationship between South African HIV-1 subtype C attenuated viruses and
rates of disease progression describes two slow progressing vertically infected siblings with
viruses comprising an unusual rev gene from a cohort of perinatally infected children at
Chris Hani Baragwanath Hospital (CHBH) in Johannesburg (Papathanasopoulos et al., 2003).
Primary viral isolates are available from a further six vertically infected children in this
cohort that have been identified as potential slow progressors. Since the date of HIV-1
infection in these children is known, it is an ideal opportunity to study disease progression in
26
this cohort. This study aims to investigate the virological features in a cohort of vertically
infected children classified as SP to determine whether slow progression is associated with
the presence of attenuated viruses harbouring defective HIV-1 genomes.
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2. MATERIALS AND METHODS
2.1. Patient samples and primary virus isolates
Primary viral isolates obtained from six antiretroviral drug-naive vertically infected children
attending a clinic at Chris Hani Baragwanath Hospital, Johannesburg, were selected for the
purposes of this study. The children fit the following definition of slow progressors:
documented infection lasting at least 6 years, asymptomatic or mild/moderate symptoms in
the absence of antiretroviral drug use. The patient epidemiological data is shown in Table
2.1. Ethical approval was obtained by Professor Tiemessen, National Institute for
Communicable Diseases, at the time of sample collection (M971010) from the University of
the Witwatersrand Committee for Research on Human Subjects. No further human ethics
was required for the purposes of this study (see Appendix A; Ethics waiver).
Infected peripheral blood mononuclear cells (PBMCs) from the six primary HIV-1 isolates
(passage one) were obtained from Professor Tiemessen, and immediately co-cultured with
2 x 106 cells/ml phytohemagglutinin (PHA)-activated donor PBMCs in 10ml RPMI-1640
(Sigma, Steinheim, Germany), supplemented with 10% fetal calf serum (FCS; Gibco, Grand
Island, USA), L-glutamine (Gibco), Penicillin/Streptomycin (Gibco) and 5% interleukin 2 (IL-2;
Roche Diagnostics, Mannheim, Germany), according to standard PBMC co-culture
techniques (Choge et al., 2006). Flasks containing the second passage (P2) of primary virus
were incubated at 37°C with 5% CO2 for 7 days. Viral isolates were maintained/fed by
removing 50% of the total culture medium volume, and replacing it with fresh medium with
IL-2 (Roche Diagnostics, Mannheim, Germany) on day 4, and monitored on day 7 for viral
growth using the Murex p24 enzyme-linked immunosorbent assay (ELISA) kit (Abbott
Murex, Dartford, UK). The expanded cultures were centrifuged at 1 400 rpm, and the
infected PBMCs (resuspended in 90% FCS (Gibco) and 10% dimethylsulphoxide (Sigma) and
supernatants were stored at -130°C and -70°C, respectively. The supernatant was stored at
–70C and used to extract viral RNA (High Pure RNA isolation kit; Roche) as required.
Proviral DNA was extracted from p24 antigen positive cultures from P2 PBMCs using the
High Pure Template Preparation Kit (Roche), as per manufacturer’s instructions. The virus
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containing supernatant from P2 was used to establish primary virus phenotypes and
biotypes by infection of MT-2 and CCR5 and CXCR4-expressing U87.CD4 cell lines,
respectively, as described previously (Cilliers et al., 2003).
2.2. Polymerase Chain Reaction and sequencing
A nested polymerase chain reaction (PCR) was carried out to amplify the virtually full-length
genomes, and LTR regions using the primers outlined in Table 2.2. The virtually full-length
genomes were amplified using the outer primers MSF12 and OMFR1 and inner primers
F2NST and OFM19 (when necessary), and cycle conditions as described previously (van
Harmelen et al., 2001), using the Expand Long Template Taq Polymerase® kit (Roche) in the
GeneAmp PCR systems 9700 thermal cycler (Applied Biosystems, Foster City, CA). A
separate LTR amplicon was generated using the outer primers JL17 and LTR3, and inner
primers VWLG-for and VWLG-rev, and cycle conditions as described previously (van
Harmelen et al., 2001), using Amplitaq Gold®(Applied Biosystems) in the GeneAmp PCR
systems 9700 thermal cycler (Applied Biosystems).
All PCR products were resolved on a 0.8% Tris acetate EDTA (TAE) agarose gel, containing
0.5µg/ml Ethidium Bromide (Promega Corporation, Madison, WI, USA) at 100V for one
hour. Gels were visualized on a UV transilluminator. All gels were run with the DNA
molecular marker II and IX mixture (Roche; range 0.07 to 23.1kb), for amplicon size
determination.
Pooled virtually full-length genome PCR products were purified on a Microcon-YM50
column (Millipore, Bedford, MA), and LTR PCR products were purified using a High Pure PCR
Product Purification Kit (Roche) as per manufacturers’ instructions. Primers spanning the
entire HIV-1 genome (Table 2.2; (Rousseau et al., 2006) were used to sequence the PCR
products in both directions. Amplicons were sequenced using the ABI Big Dye terminator
system (version 3.1) according to manufacturer’s instructions (Applied Biosystems) using
4μl of ready reaction mix, 2μl of 5x sequencing buffer and 1μl of each sequencing primer
(3.2 pmol), PCR template, and ddH2O to a final volume of 20μl. Reactions were placed in a
MicroAmp 96-well optical reaction plate (Applied Biosystems). Terminator reactions were
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then carried out with 25 cycles of 960C for 10 seconds, 500C for 5 seconds and 600C for 4
minutes in the GeneAmp PCR systems 9700 thermal cycler (Applied Biosystems).
Sequencing reaction products were immediately purified of unincorporated dyes
terminators, salts and dNTPs using isopropanol precipitation. Briefly, 80μl of 80%
isopropanol (Merck,) was added to each well (containing 20 μl), mixed well and incubated in
the dark for 15 minutes. The plate was then centrifuged at 2000Xg for 45 minutes,
immediately inverted on a paper towel and centrifuged for a further 1 minute at 700xg. The
plate was air-dried, and the purified sequencing products were resuspended in 10μl Hi-Di
Formamide (Applied Biosystems). Sequencing plates were run on the ABI Prism 3100®
Genetic Analyzer (Applied Biosystems), using a 50cm capillary filled with POP-6 polymer gel
(Applied Biosystems).
2.3. Genome and Phylogenetic Analysis
All generated sequence data was edited using the Sequencing analysis 3.3 program (Applied
Biosystems), and the near full-length and LTR sequences were assembled using
Sequencher®4.5 (Genecodes, Ann Arbor, MI) to yield the complete full-length genome
sequence in one contig. A multiple alignment of the near full-length genomes with reference
sequences from HIV-1 subtypes A to K, and CRF01_AE and CRF02_AG (http://hiv-
web.lanl.gov), were generated using Clustal X (version 1.83)
(http://www.ebi.ac.uk/Tools/clustalx). The LTR regions were analysed in a separate clustal X
alignment, since LTR data was not available for all the reference subtypes. Gaps were
stripped prior to phylogenetic analysis. Neighbor-Joining phylogenetic trees were
constructed in MEGA 4 (http://www.megasoftware.net) with the Kimura two-parameter
model, and a transition/transversion ratio of 2.0. The stability of the nodes was assessed by
bootstrap analysis (100 replicates). Bootstrap values greater than 70% were considered
significant.
Similarity plots were performed against representative strains from each subtype using the
RIP (recombinant Identification Program) 3.0 program in the Los Alamos database, with
sliding windows of 300 nucleotides (http://hiv-web.lanl.gov). The nucleotide sequences and
predicted amino acids for all the HIV-1 proteins of all isolates were analysed and known
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functional motifs were identified. The sequences were annotated and submitted to
Genbank using Sequin (http://www.ncbi.nlm.nih.gov/Sequin).
Table 2. 2: Epidemiological and clinical data of HIV-1 vertically infected children attending
Chris Hani Baragwanath Hospital in Johannesburg, identified as potential slow progressors.
Sample ID Age (yrs)* Gender Viral load
(RNA copies/ml)
CD4 cell
Count (cells/μl)
LT5 7 Female 1074 866
LT21 9 Female 6 588 546
LT39 7 Female 12180 760
LT42 8 Male 23564 416
LT45 7.2 Male 5524 410
LT46 10 Male 6024 467
*at time sample was taken
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Table 2.2: Primers used for PCR amplification and sequencing of the near full-length
genomes and LTR amplicons.
Primer name Primer sequence 5’-3’ Used for:
MSF12 (outer)
OMFR1 (outer)
F2NST (inner)
OFM19 (inner)
AAATCTCTAGCAGTGGCGCCCGAACAG
TGAGGGATCTCTAGTTACCAGAGTC
GCGGAGGCTAGAAGGAGAGAGATGG
GCACTCAAGGCAAGCTTTATTGAGGCTTA
Near full length PCR (van Harmelen et
al., 2001)
JL17 (outer)
LTR3 (outer)
VWLG-for (inner)
VWLG-rev (inner)
CATTCTGCAGCTTCCTCATTGAT
ACTGTCTAGATGGATGGTGCTWCAAGYTAGT
AGATGCTGCATATAAGCAGCYGC
TCTTTCCCCCTGGCCKTAAC
LTR PCR (F. McCutchan, pers. comm.)
U5Cc
U5Cd
3_3_PlCb
3_3_pICb
2.U5Cd
SQ2FC
SQ2FC(2)
SQ3FC(2)
SQ4F
SQ5F
SQ6F
SQ6.5FC
SQ7F(2)
SQ8FC
SQ9FC(3)
SQ10FC
SQ11F
SQ11FC
SQ12F
DR7C
SQ13F(2)C
SQ14FC
SQ15FC
SQ16F
2.3_3_plCb
SQ2R
SQ3R(2)C
SQ3RC
SQ5.5RC
4R(2)C
5R(3)C
SQ6RC
SQ6RC(2)
SQ7R(2)C
SQ8R
SQ9’RC
SQ9RC(3)
SQ8RC
SQ10RC
RTC
SQ11RC(3)
SQ11RC(4)
SQ12R
HIP202
13R(2)C(2)
14R(3)C
SQ15R
SQ16RC
ED31
DR7
DR8
BH2
1.5_5_PLC
1.3_3_ProC
CCTTGAGTGCTCTAAGTAGTGTGTGCCCGTCTGT
AGTAGTGTGTGCCCGTCTGTTGTGTGACTC
ACTACTTAGAGCACTCAAGGCAAGCTTTATTG
TAGAGCACTCAAGGCAAGCTTTATTGAGGCTTA
AGTAGTGTGTGCCCGTCTGTTGTGTGACTC
CTTCAGACAGGAACAGAGGA
GAGGAAGAACAAAACAAAAGTCAG
GGGAGACATCTATAAAAGATGGATAA
ACAGGCTAATTTTTTAGGGA
AAACAATGGCCATTAACAGAAGAGA
CTTTGGATGGGTTATGAACT
GCAGAGTTAGAATTAGCAGAGAACAG
AGGAGCAGAAACTTTCTATGTAGATGG
CCTGGTAGCAGTCCATGTAGC
CAGGTAGACAGGATGAAGATCAGAAC
GGAGCCAGTAGATCCTAACCTAGAG
ACTCTATTTTGTGCATCAGA
TCTATTCTGTGCATCAGGTGCTAAAGCATA
CCTCAGCCATTACACAGGCCTGTCCAAAG
TCAACTCAACTACTGTTAAATGGTAGCCTAGC
TATATAAATATAAAGTGGTAGAAATTAAGC
ACTCACGGTCTGGGGCATTA
GAGAGCGGTGGAACTTCTGG
CCACACACAAGGCTACTTCC
TAGAGCACTCAAGGCAAGCTTTATTGAGGCTTA
CACCATCCAAAGGTCAGTGG
GCTATGGTATCAAGCAGACTAATAGCACTC
TTTAGTTCCAGACCCCAATA
CTAGGAGCTGTTGATCCTTTAGGTAT
GTTGATCCCTTAGGTATCTTTCTA
CATTGCTCGTCCTACCCCCTGCCAC
ATAATGTATAGGAATCGGGT
GAATTGGGTCAAAAGAGACCTTTGGA
CTGTGGGTACACAGGCATGTGTAGC
CTCCGCTTCTTCCTGCCATAGGAGAT
ATATGAATTAGTTGGTCTGCCAGGCC
TTGGATGTCTGCTTTCATAATGAT
TTCTACTACTCCCTGACTTTGGGGAT
GCCATTGTCTGTATGTATTACTTTGACTG
CATTTGTCAGGATGGAGTTCATA
TTTAGGAGTCTTTCCCCATATTACTAT
GCTTGTAATTCAGTCTTCTGATTTGTTG
TGTATGTCATTGACAGTCC
CTAATACTGTATCATCTGCTCCTGT
GTGTTATATGGATTTTCAGGCCC
TCGAATCTGAAGCTCTCTGCTGGTG
TTTGGTCCTTGTCTTATGTCCAGAATGC
CTTGTCTAGGGCTTCCTTGGT
CCTCAGCCATTACACAGGCCTGTCCAAAG
TCAACTCAACTGCTGTTAAATGGCAGTCTAGC
CACTTCTCCAATTGTCCCTCATATCTCCTCC
CCTTGGTGGGTGCTACTCCTAATGGTTCA
GGGTCTCTCTAGGTAGACCAGATCTGAG
AGGGTCTGAGGGATCTCTAGTTACCAGAG
Sequencing (Rousseau et al., 2006)
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3. RESULTS
The HIV-1 primary virus isolates from six vertically infected children were successfully
expanded using PHA-stimulated donor PBMCs. All six isolates were found to utilize the CCR5
coreceptor for cell entry, and exhibited the NSI phenotype (Table 3.1). Proviral DNA was
successfully extracted and used to PCR amplify the near full-length genomes and LTR
fragments (Figure 3.1). The near full-length genomes were amplified by nested PCR to yield
an approximately 9.5 kb amplicon (Figure 3.1; Lanes 1 to 5), whereas for the LTR amplicons,
the yield for all but one sample was adequate after the first round. The first round LTR
amplicon was the expected size of approximately 1.2kb (Figure 3.1; Lanes 6 to 9), and
second round amplicon was approximately 0.45kb (Figure 3.1; Lane 10). All amplicons were
purified and successfully sequenced.
Agarose gel PCR products
23.1 kb
9.4 kb
1.3 kb
1.0 kb
~1.2 kb
0.6 kb
~0.45 kb
M 1 2 3 4 5 6 7 8 9 10 M
M-MW marker
1-5: Near-full length
6-10: LTR regions
Figure 3.1: Representative agarose gel electrophoresis (1%) of the near full-length PCR (~9.5
kb, Lanes 1 to 5) and LTR PCR amplicons (~0.45-1.2 kb, Lanes 6 to 10) from the newly
characterized HIV-1 subtype C isolates. The sizes of the molecular weight marker (M; Roche)
are indicated in kilobases (kb) on the right.
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Extensive sequence analysis revealed that all six full-length genomes encoded for the
correct open reading frames (ORFs), and ranged from 9703 to 9767bp in length (Table 3.1).
Nucleotide sequences for the full-length genomes were submitted to Genbank and are
available under the accession numbers listed in Table 3.1. Phylogenetic analysis for the near
full-length genomes and the LTR regions showed that all six isolates clustered within
subtype C with a bootstrap value of 100% (Figures 3.2 and 3.3, respectively). In addition, all
six isolates were subtype C throughout their genomes by similarity plots (Appendix B).
The nucleotide sequences and predicted amino acids for all the HIV-1 proteins of all six
isolates were extensively analyzed and compared to each other to identify aberrant
genes/proteins. All isolates were found to have unusual genes/proteins (listed in Table 3.1).
An alignment of the predicted amino acid sequences for the unusual integrase, vpr, tat ,rev
and nef genes are shown in Figures 3.4, 3.5, 3.6, 3.7 and 3.8 respectively. A description of
the single letter amino acid (aa) sequence code is shown in Appendix C. The consensus C
and ancestral C sequences were used for comparative purposes. Isolate LT39 had a four
amino acid sequence extension at the C terminus of Integrase (IN) (Figure 3.4). Isolate LT5
has a 2aa insertion in the mitochondriotoxic domain of Vpr, and isolates LT21 and LT42
contain the H77Q and LT45 has the A77Q polymorphism in Vpr (Figure 3.5). Isolate LT21
contained an additional 5aa in the C-terminus of tat exon 2 (Figure 3.6). Rev in isolates LT45
and LT46 had a 3aa extension (Figure 3.7). Isolate LT5 contains the Nef N9S mutation and
the Nef ExxxLM motif is disrupted in LT46 (Figure 3.8). There were no obvious “defects” in
the LTR regions, and remainder coding regions of the genome for all isolates (results not
shown).
Analysis of the polymerase gene nucleotide sequences for the presence of antiretroviral
(ARV) drug resistance mutations (Stanford database, http://hivdb.stanford.edu) revealed
that no resistance mutations to RT or protease inhibitors were found, with the exception of
V82A in the protease of LT46, which has been associated with phenotypic resistance to
ritonavir, indinavir, nelfinavir and lopinavir in vitro.
The V3 loop region of the envelope glycoprotein (gp120) is involved in coreceptor usage,
thus the predicted V3 amino acid sequences were extensively analyzed and compared
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(Figure 3.9). The length, overall positive charge, amino acids at positions 11 and 25 and
tetrapeptide motif at the tip of the V3 loop, are characteristic of CCR5 utilizing envelopes,
and correctly correlated with the phenotype/biotype of each primary isolate (Table 3.1).
Table 3.1: Overview of biological and genotypic data obtained for the six newly
characterized primary viral isolates from slow progressors.
Isolate
name
Biotype/
Phenotype
Full length
Genome
(nucleotides)
Subtype Genotypic
Resistance
profile2
Unusual
genes
GenBank
Accession
number
99ZALT5 R5/NSI 9767 C None vpr EU293445
99ZALT21 R5/NSI 9723 C None vpr, tat EU293446
99ZALT39 R5/NSI 9744 C None integrase EU293447
99ZALT42 R5/NSI 9729 C None vpr EU293448
99ZALT45 R5/NSI 9703 C None vpr, rev EU293449
99ZALT46 R5/NSI 9762 C V82A in PR rev, nef EU293450
1R5/NSI: CCR5-utilizing, non-syncytium inducing.
2ARV drug naive, V82A reduces susceptibility to ritonavir, indinavir, nelfinavir and lopinavir
in vitro.
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Figure 3.2: Phylogenetic relationships of the near full-length genomes of the six newly
characterized subtype C viruses, with HIV-1 group M subtype reference sequences from the Los
Alamos database. The newly sequenced genes are shown in blue italics. Phylogenetic trees were
constructed from nucleotide alignments, using neighbour joining and the Kimura two-parameter
distance matrix. The reliability of the branching order was estimated from 100 bootstrap
replicates, and only bootstrap values of 70% or higher are shown.
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Figure 3.3: Phylogenetic relationships of the LTR regions of the six newly characterized subtype C
viruses with HIV-1 subtype reference sequences from the Los Alamos database. The new sequences
are shown in blue italics. Only bootstrap values of 70% or higher are shown. Phylogenetic trees were
constructed from nucleotide alignments, using neighbour joining and the Kimura two-parameter
distance matrix. The reliability of the branching order was estimated from 100 bootstrap replicates,
and only bootstrap values of 70% or higher are shown.
37
Figure 3.4: Alignment of the predicted amino acid sequences for the Integrase enzymes
from the six newly characterized subtype C viruses and comparison to the consensus C and
ancestral C sequences obtained from Los Alamos (www.hiv.lanl.gov). The unusual motif at
the C-terminus of the LT39 integrase enzyme is shown in blue. The dots represent identical
amino acids, and dashes indicate insertions/deletions.
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Figure 3.5: Alignment of the predicted amino acid sequences for the viral protein R (Vpr)
from the six newly characterized subtype C viruses and comparison to the consensus C and
ancestral C sequences obtained from Los Alamos (www.hiv.lanl.gov). The unusual 2 amino
acid insertion at the C-terminus of LT5 Vpr is shown in red. Position 77 is highlighted in blue.
The dots represent identical amino acids, and dashes indicate insertions/deletions.
Figure 3.6: Alignment of the predicted amino acid sequences for Tat from the six newly
characterized subtype C viruses and comparison to the consensus C and ancestral C
sequences obtained from Los Alamos (www.hiv.lanl.gov). The unusual motif at the C-
terminus of LT21 is shown in blue. The cysteine rich motif is highlighted in red. The dots
represent identical amino acids, and dashes indicate insertions/deletions.
39
Figure 3.7: Alignment of the predicted amino acid sequences for Rev from the six newly
characterized subtype C viruses and comparison to the consensus C and ancestral C
sequences obtained from Los Alamos (www.hiv.lanl.gov). The unusual three amino acid
insertion at the C-terminus of LT45 and LT46 is shown in blue. The dots represent identical
amino acids, and dashes indicate insertions/deletions.
Figure 3.8: Alignment of the predicted amino acid sequences for Nef from the six newly
characterized subtype C viruses and comparison to the consensus C and ancestral C
sequences obtained from Los Alamos (www.hiv.lanl.gov). Position 9 is highlighted in pink,
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and the ExxCLL motif is shown in blue. The dots represent identical amino acids, and dashes
indicate insertions/deletions.
Figure 3.9: Alignment of the predicted V3 amino acid sequences of the 6 newly
characterized HIV-1 subtype C isolates. The sequences are compared to the HIV-1 subtype C
consensus and ancestral sequence (www.hiv.lanl.gov). The overall positive charge, number
of amino acids, phenotype and biotype of each isolate is shown on the right. Dashes (-)
indicate deletions/insertions, and positions 11 (green) and 25 (pink) and the V3 crown/tip
(yellow) are highlighted.
Isolate V3 loop sequence # aa Charge Phenotype Coreceptor
usage
11 25
CONSENSUS C: CTRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAHC
C.anc : ...................................
LT21 : .I................S.H...E...N......
LT45 : .S.IG....T..G.....A.F.......N..K...
LT39 : .I.......E........A.....G..........
LT42 : ....G....Q........A..-.NN..........
LT46 : ....S......V......A.F...E..........
LT5 : .I.TG......V...........DG......K.Y.
35
35
35
35
35
34
35
35
+5
+5
+6
+4
+3
+4
+4
+3
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
CCR5
CCR5
CCR5
CCR5
CCR5
CCR5
CCR5
CCR5
41
4. DISCUSSION
In this study we have shown that the six primary HIV-1 subtype C viruses isolated from
potential SP or LTNP all harboured potentially defective genomes. Analysis of the
polymerase gene nucleotide sequences for the presence of ARV drug resistance mutations
revealed that no resistance mutations to RT or protease inhibitors were found, with the
exception of V82A in the protease of LT46, which reduces susceptibility to ritonavir,
indinavir, nelfinavir and lopinavir in vitro (Larder et al., 2000; Shafer, Stevenson, and Chan,
1999). The presence of V82A in untreated individuals has been reported
(http://hivdb.stanford.edu), and since protease inhibitors were not available in the public
sector in South Africa at the time of sample collection, it is highly likely that this patient was
ARV drug naïve. Thus, these patients were all considered to be ARV drug naïve, ruling out
the possibility that antiretroviral therapy contributed to the delayed disease progression in
these children.
Nucleotide and predicted amino acid sequence analysis revealed all viruses had open
reading frames for all genes and encoded for proteins of the expected length, with several
exceptions. Overall, patients LT5, LT21 and LT42 contain HIV-1 harboring Vpr with
altered/decreased pro-apoptotic activity. Furthermore, HIV-1 from patient LT21 exhibited
an unusual tat exon 2 variant which could alter tat-mediated Reverse transcription. Patient
LT39 is infected with HIV-1 containing IN with potentially altered efficiency for full site
integration. Finally, patients LT45 and LT46 harbored virus with an ECC extension in Rev
which may alter Rev structure, impairing its ability to bind to RNA and other cellular factors
or prevent ternary complex disassembly. In addition, the HIV-1 Nef from patient LT46
contains a disrupted ExxxLM motif which may render LT46 Nef unable to bind adaper
protein 1 (AP-1), and therefore inactive on CD4 endocytosis. It is possible that these
alterations lead to altered viral replication which impacts on disease progression in these
children.
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The four amino acid (aa) QNME extension in the IN of LT39 was unique to this isolate. IN
mediates the integration of cDNA into the host chromosome, an essential step in HIV
replication(reviewed in (Asante-Appiah and Skalka, 1999). Integration is mediated by a large
nucleoprotein complex (PIC) containing viral DNA, Vpr , IN and several cellular proteins such
as HMGa1 (Harris and Engelman, 2000), IN-1/SNF5 (Kalpana et al., 1994) and LEDGF/p75
(Rahman et al., 2007). The recognition sequence for the integrase enzyme was located at
the ends of the viral LTRs (Roth, Schwartzberg, and Goff, 1989) binding to which requires at
least a cross-linked tetrameric form of integrase to perform full-site integration (Faure et al.,
2005). Integration of proviral DNA occurs preferentially into transcriptional units of active
genes (Schroder et al., 2002). Centromeres and telomeres are not favoured targets
(Carteau, Hoffmann, and Bushman, 1998). IN catalyzes the integration of viral cDNA into the
host chromosome via 3’ processing and strand transfer: the first is by processing the 3’ ends
of linear viral cDNA in which the GT nucleotide pairs of the viral DNA are removed leaving a
CA dinucleotide at each 3’end (occurs in the cytoplasm), and the second is the strand
transfer (or joining reaction) in which the processed viral DNA ends are inserted into host
DNA (occurs in the nucleus). The C-terminal region of IN is involved in non-specific DNA
binding. It is also important for oligomerization of the enzyme and is necessary since IN
monomers/dimers can only integrate one side of the LTR. It is possible that the tetrapeptide
QNME insertion identified at the C terminus of IN from isolate LT39 disrupts IN
oligomerization, thereby altering the efficiency of the full site integration activity.
Viral protein R (Vpr) is responsible for multiple functions of HIV-1, including nuclear import
of the pre-integration complex, apoptosis, fidelity of the RT process, G2 cell cycle arrest and
transactivation of the LTR and/or target genes thereby controlling HIV-1 gene expression
(Cui et al., 2006). The 96 amino acid Vpr protein is packaged into the HIV-1 virion and
released into the cytoplasm during initial cell infection where it can exert its actions. The vpr
gene exhibits a wide range of naturally occurring polymorphisms (reviewed in (Tungaturthi
et al., 2004), and the association between these and disease progression warrants further
investigation. The Vpr R77Q mutation has been associated with long term non progression
and affects the mitochondriotoxic domain of the wild type gene which has been shown to
induce T cell apoptosis (Lum et al., 2003), and has been argued to be necessary for virulence
(Brenner and Kroemer, 2003). Isolate LT5 has a unique 2aa insertion in the
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mitochondriotoxic domain of Vpr. Previous research showed that R77Q was associated with
slower disease progression, by decreasing the pro-apoptotic activity of Vpr (Lum et al.,
2003). Isolates LT21 and LT42 contain H77Q, which represents a conservative amino acid
change vs R77Q. Thus, these three isolates likely contain Vpr with altered/decreased pro-
apoptotic activity. Interestingly, Vpr has neurotoxic effects (Jones et al., 2007) and a
defective vpr gene has recently been implicated in HIV-1 dementia (Thomas et al., 2007).
The tat viral gene is mainly responsible for transactivation of HIV-1 gene expression in
conjunction with the TAR element, (Bannwarth and Gatignol, 2005) and other diverse Tat
functions have been reviewed in (Harrich et al., 2006). Tat is encoded by two exons, and in
natural infection both Exon 1 and Exon 2 are transcribed by cells, so different forms have
different molecular functions. Tat exon 1 is highly conserved and its main function is to
mediate transactivation of the viral LTR promoter. It can also induce monocyte chemotaxis
and protein-protein interactions as well as uptake of soluble tat by cells. Exon 2 conveys
improved viral replication and has been implicated in chemoattraction of monocytes and
dendritic cells (Izmailova et al., 2003), in cell adhesion and binding to cell surface integrins,
modulation of MHC class I gene expression, ability to inhibit reverse transcription, tat
mediated apoptosis (Peruzzi, 2006), neurotoxicity (Sabatier et al., 1991) and can bind
human translation elongation factor 1 delta (Xiao et al., 1998). Isolate LT21 contained an
additional 5aa in the C-terminus of tat exon 2. There are no previous reports of a 5 aa
extension in the databases (rarely see 4 aa). Tat exon 1 has been shown to facilitate the first
strand transfer reaction of RT to cDNA, while Tat exon 2 (regions 86 to 101) inhibits cDNA
synthesis when tat concentrations reach a critical level. Future work needs to elucidate
whether the LT21 tat exon 2 (86 to 106) variant is an enhancer or suppressor of tat-
mediated reverse transcription.
Rev initiates the late phase of virus gene expression by interacting with the RRE on the full
length 9 kb and singly spliced 4 kb viral RNA transcripts, and their nuclear import and export
is mediated by binding of the Rev nuclear localization signal to importin β, or the Rev
nuclear export signal to Crm1/Exportin-1, respectively. Rev thus plays a critical role for the
production of HIV-1 structural proteins (reviewed in (Cochrane, 2004). Rev in isolates LT45
and LT46 had a 3aa extension. There are only two other reports of this Rev polymorphism:
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the SBBC LTNP viruses (Churchill et al., 2007), and SP from vertically infected siblings (TM10
and TM45) from the same cohort in South Africa (Papathanasopoulos et al., 2003). Rev
activity is defined by domains or motifs for nuclear export of RNA, RNA binding, and nuclear
import signals, which have been shown to be conserved during vertical transmission
(Ramakrishnan et al., 2005). Thus the presence of the ECC extension may alter Rev
structure, impairing its ability to bind to RNA and other cellular factors or prevent ternary
complex disassembly.
The functions of nef have been reviewed in (Das and Jameel, 2005). Nef causes endocytosis
and lysosomal degradation of CD4 and downregulation of MHC class I and II. The leucine
residues in the Nef ExxxLL motif are required for CD4 downregulation and are involved in
the interaction with adapter protein 1 (AP-1). This motif is disrupted in LT46 (ExxxLM). This
may render LT46 Nef unable to bind AP-1, and therefore inactive on CD4 endocytosis. Thus,
no/low degradation of CD4 in an infected cell will most likely impact on the production of
infectious virions. Nef gene deletions are probably the most extensively studied, since the
initial identification of this deletion in adult LTNPs in the SBBC (Deacon et al., 1995). In
addition, the cAMP-dependent kinase PKA phosphorylation site in Nef of LT5 is altered. Nef
aberrations have been well described (Brambilla et al., 1999) and frequently involve the LTR
regions of the viral genome, the inability of the virus to cause downregulation of MHC and
CD4 molecule may contribute to immune recognition of the infected cells, subsequent
cytotoxicity, and lead to host resistance. In contrast, variations in nef dependant epitopes
have been shown to facilitate immune escape and an attenuated response of the cytotoxic
T-lymphocytes (Ueno et al., 2007). Nef mutations have recently been linked to different
rates of disease progression in children (Walker et al., 2007). The latter studies were in a
cohort of 34 children and sequencing was notably done only on the nef gene.
Overall, this study describes the identification of six potential HIV-1 subtype C attenuated
viruses and unusual genes coding for possibly defective Integrase, Vpr, Tat, Rev and Nef
proteins that may affect viral replicative capacity which may be partly attributed to the long
term survival of these children. However, as mentioned previously there are many
confounding variables which contribute to long-term non progression of HIV-1 infected
individuals. This study concentrates on the genotypic characteristics of the infecting viral
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isolates but that is not to say that this is the sole determinant which contributes to the
extended survival of these patients. Importantly, this study provides clues on future
function analysis to establish an association between structural or functional alterations in
various HIV-1 proteins and their impact on disease progression.
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Appendix B: Similarity plots of the full length genome sequences of the 6 newly characterized
sequences, confirming they were HIV-1 subtype C. The test sequence is compared to
consensus sequences of all subtypes, and the sequence it shares the most homology with is
shown closest to s(k) values of 1.
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Appendix C: Amino acid codes
